Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies - Poll - MDSpire

Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies

  • By

  • Piyanoot Jitthiang

  • Rattanavit Phandthong

  • Ployploen Phikulsod

  • Siwanon Jirawatnotai

  • Narongsak Kiatikajornthada

  • Harit Suwanrusme

  • April 30, 2026

  • 0 min

Share

Original Source(s)

Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies

  • by Piyanoot Jitthiang, Rattanavit Phandthong, Ployploen Phikulsod, Siwanon Jirawatnotai, Narongsak Kiatikajornthada, Harit Suwanrusme

  • April 30, 2026

Related Content

Potential targets for boron transport in boron neutron capture therapy

FOXA2 in cancer: from fundamental biology to clinical translation

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort